These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19005155)

  • 1. Successful treatment with bosentan of non-digital skin ulcers in severe scleroderma.
    Ferreira ME; Scheinberg MA
    Ann Rheum Dis; 2008 Dec; 67(12):1784-5. PubMed ID: 19005155
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy.
    Tillon J; Hervé F; Chevallier D; Muir JF; Levesque H; Marie I
    Br J Dermatol; 2006 May; 154(5):1000-2. PubMed ID: 16634913
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of Bosentan in treatment of refractory sclerodermic bone prominences skin ulcers.
    Richetta AG; Mattozzi C; Maiani E; D'Epiro S; Cimillio M; Carboni V; Giancristoforo S; Calvieri S
    Clin Ter; 2008; 159(5):317-9. PubMed ID: 18998033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
    Korn JH; Mayes M; Matucci Cerinic M; Rainisio M; Pope J; Hachulla E; Rich E; Carpentier P; Molitor J; Seibold JR; Hsu V; Guillevin L; Chatterjee S; Peter HH; Coppock J; Herrick A; Merkel PA; Simms R; Denton CP; Furst D; Nguyen N; Gaitonde M; Black C
    Arthritis Rheum; 2004 Dec; 50(12):3985-93. PubMed ID: 15593188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan as a rescue therapy in scleroderma refractory digital ulcers.
    Chamaillard M; Heliot-Hosten I; Constans J; Taïeb A
    Arch Dermatol; 2007 Jan; 143(1):125-6. PubMed ID: 17224564
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of the endothelin receptor blocker bosentan for refractory sickle cell leg ulcers.
    Lionnet F; Bachmeyer C; Stankovic K; Tharaux PL; Girot R; Aractingi S
    Br J Haematol; 2008 Sep; 142(6):991-2. PubMed ID: 18671710
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients.
    García de la Peña-Lefebvre P; Rodríguez Rubio S; Valero Expósito M; Carmona L; Gámir Gámir ML; Beltrán Gutiérrez J; Díaz-Miguel C; Orte Martínez J; Zea Mendoza AC
    Rheumatology (Oxford); 2008 Apr; 47(4):464-6. PubMed ID: 18263597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bosentan and sildenafil: successful treatment in a sclerodermic patient with refractory ulcers.
    Catarsi E; Doveri M; Tavoni A
    Reumatismo; 2013 May; 65(2):79-81. PubMed ID: 23877412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon.
    Moore TL; Vail A; Herrick AL
    Rheumatology (Oxford); 2007 Feb; 46(2):363-4. PubMed ID: 17116656
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
    Nguyen VA; Eisendle K; Gruber I; Hugl B; Reider D; Reider N
    Rheumatology (Oxford); 2010 Mar; 49(3):583-7. PubMed ID: 20040526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of bosentan on nondigital ulcers in patients with systemic sclerosis.
    Taniguchi T; Asano Y; Hatano M; Tamaki Z; Tomita M; Kawashima T; Miyazaki M; Sumida H; Akamata K; Takahashi T; Ichimura Y; Toyama T; Sugita M; Noda S; Yao A; Kinugawa K; Sato S
    Br J Dermatol; 2012 Feb; 166(2):417-21. PubMed ID: 21848685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial.
    Kuhn A; Haust M; Ruland V; Weber R; Verde P; Felder G; Ohmann C; Gensch K; Ruzicka T
    Rheumatology (Oxford); 2010 Jul; 49(7):1336-45. PubMed ID: 20371505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bosentan: new indication. Scleroderma and finger ulcers: no tangible efficacy.
    Prescrire Int; 2008 Dec; 17(98):238. PubMed ID: 19422150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study.
    Tsifetaki N; Botzoris V; Alamanos Y; Argyriou E; Zioga A; Drosos AA
    J Rheumatol; 2009 Jul; 36(7):1550-2. PubMed ID: 19567637
    [No Abstract]   [Full Text] [Related]  

  • 15. Endothelin receptor antagonism-based treatment for scleroderma renal crisis.
    Izzedine H; Rouvier P; Deray G
    Am J Kidney Dis; 2013 Aug; 62(2):394-5. PubMed ID: 23769136
    [No Abstract]   [Full Text] [Related]  

  • 16. Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis.
    Dhillon S
    Drugs; 2009 Oct; 69(14):2005-24. PubMed ID: 19747014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Digital necrosis in scleroderma].
    Fain O
    Rev Prat; 2007 Feb; 57(4):359. PubMed ID: 17455736
    [No Abstract]   [Full Text] [Related]  

  • 18. Basic fibroblast growth factor treatment for skin ulcerations in scleroderma.
    Yamanaka K; Inaba T; Nomura E; Hurwitz D; Jones DA; Hakamada A; Isoda K; Kupper TS; Mizutani H
    Cutis; 2005 Dec; 76(6):373-6. PubMed ID: 16438426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bosentan is effective against digital ulcerations and hyperkeratosis in systemic sclerosis.
    Kurgyis Z; Varga R; Sick I; Lang MU; Ruzicka T; Sárdy M
    Acta Derm Venereol; 2011 Oct; 91(6):716-7. PubMed ID: 21879251
    [No Abstract]   [Full Text] [Related]  

  • 20. [Management of digital ulcers in patients with systemic sclerosis].
    Riemekasten G; Hoffmann U; Sunderkötter C; Weiss N; Kuhn A;
    Dtsch Med Wochenschr; 2012 Jan; 137(1-2):34-40. PubMed ID: 22180282
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.